Systemic administration of IL-33 induces a population of circulating KLRG1hi type 2 innate lymphoid cells and inhibits type 1 innate immunity against multiple myeloma.
Abstract
ILC2s and inhibits type 1 immunity against multiple myeloma. These results argue against therapeutic administration of IL-33 to myeloma patients.
| Authors | Guillerey, Camille; Stannard, Kimberley; Chen, Jason; Krumeich, Sophie; Miles, Kim; Nakamura, Kyohei; Smith, Jessica; Yu, Yuan; Ng, Susanna; Harjunpää, Heidi; Teng, Michele W L; Engwerda, Christian; Belz, Gabrielle T; Smyth, Mark J |
|---|---|
| Journal | IMMUNOLOGY AND CELL BIOLOGY |
| Pages | 65-83 |
| Volume | 99 |
| Date | 1/08/2020 |
| Grant ID | 1122183 |
| Funding Body | Cancer Australia |
| URL | http://www.ncbi.nlm.nih.gov/pubmed/?term=10.1111/imcb.12390 |
| Download Article |